Inhaled magnesium fluoride reverse bronchospasma

Area of Science:

• Pharmacology
• Respiratory Medicine
• Toxicology

Background:

• Asthma is a prevalent global respiratory condition with increasing severity and resistance to standard beta(2) agonist treatments.
• There is a critical need for novel therapeutic agents to mitigate the morbidity associated with asthmatic diseases.
• Methacholine (MeCh) is a common agent used to induce bronchial constriction in animal models for respiratory research.

Purpose of the Study:

• To evaluate and compare the efficacy of inhaled magnesium fluoride (MgF(2)) against magnesium sulphate (MgSO(4)) and sodium fluoride (NaF) in a rat model of methacholine-induced bronchoconstriction.
• To determine the bronchodilating potential of MgF(2) when administered alone or in combination with different solutions (NaCl 0.9% or acetic acid).

Main Methods:

• Fifty-six Wistar rats were randomly assigned to five inhalation groups: MeCh only, MgF(2) + NaCl 0.9%, MgF(2) + acetic acid, MgSO(4) 15% alone, and NaF 0.5 M alone.
• Airway resistance was measured using pneumomultitest equipment following incremental doses of methacholine.
• Comparative analysis of bronchodilatory effects was performed between the different treatment groups.

Main Results:

• MgF(2) (with NaCl or acetic acid) and MgSO(4) significantly reversed methacholine-induced bronchial constriction, exhibiting immediate bronchodilating effects.
• MgF(2) combined with acetic acid demonstrated a statistically greater reduction in bronchial resistance compared to MgF(2) with NaCl, NaF alone, and MgSO(4) alone (P<0.05).
• Inhaled NaF alone also produced a significant bronchodilating effect, becoming apparent from the sixth dose of methacholine (17 mg/L).

Conclusions:

• Inhaled magnesium fluoride, particularly when dissolved in acetic acid and delivered as an aerosol, effectively reduces bronchial spasm.
• MgF(2) shows promise as a bronchodilator for managing respiratory conditions characterized by bronchospasm, including asthma and chronic obstructive pulmonary disease (COPD).
• Further research into MgF(2) as a therapeutic agent for obstructive airway diseases is warranted.